Skip to main content Accessibility help
  • Print publication year: 2013
  • Online publication date: June 2014


Related content

Powered by UNSILO

Suggested reading

Aweeka FT, Gottwald MD, Gambertoglio JG, Wright TL, Boyer TD, Pollock AS, Eldon MA, Kuglar AR, Alldredge BK. Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia 1999; 40: 777–782.
Boucher BA, Bombassaro A, Rasmussen SN, Watridge CB, Achari R, Turlapaty P. Phenytoin prodrug 3-phosphoryloxy-methyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration. Journal of Pharmacological Sciences 1989; 78: 923–932.
Eldon MA, Loewen GR, Voigtman RE, Holmes GB, Hunt TL, Sedman AJ. Safety, tolerance, and pharmacokinetics of intravenous fosphenytoin. Clinical Pharmacology and Therapeutics 1993; 53: 212.
Leppik IE, Boucher BA, Wilder BJ, Murthy VS, Watridge C, Graves NM, Rask CA, Turlapaty P. Pharmacokinetics and safety of a phenytoin prodrug given IV in patients. Neurology 1990; 40: 456–460.
Pryor FM, Gidal B, Ramsay RE, DeToledo J, Morgan RO. Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses. Epilepsia 2001; 42: 245–250.